Cellavision Reports Results Above Expectations, Increases Dividend

Blood analysis company Cellavision has reported stronger-than-expected figures for the fourth quarter. The board is proposing an increased dividend.

Revenue rose by 5.3 percent to 197 million kronor (187). The outcome can be compared with the Factset analyst consensus, which was 192. Organic sales growth was 12.2 percent (-7).

The EBITDA result was 65 million kronor (61), expected was 60, with an EBITDA margin of 33.0 percent (32.6).

Operating profit was 55 million kronor (51). The operating margin was 27.9 percent (27.3).

Profit before tax was 55 million kronor (51).

Profit after tax amounted to 43 million kronor (41).

Earnings per share amounted to 1.79 kronor (1.72).

The ordinary dividend proposed is 2.75 kronor per share (2.50). The expected figure was 2.65.

Cash flow from operating activities amounted to 51 million kronor (46).

"During the quarter, we made progress within our strategic focus areas and maintained a high level of activity within our research and development portfolio, which showed promising results," said CEO Simon Østergaard.

He states that investments in the innovation area are developing according to plan.

Cellavision, Mkr	Q4-2025	Consensus	Change vs consensus	Q4-2024	Change
Net revenue	197	192	2,6%	187	5,3%
Organic sales growth, percent	12,2			-7
EBITDA	65	60	8,3%	61	6,6%
EBITDA margin	33,0%	31,3%		32,6%
Operating profit	55			51	7,8%
Operating margin	27,9%			27,3%
Profit before tax	55			51	7,8%
Net profit	43			41	4,9%
Earnings per share, kronor	1,79			1,72	4,1%
Cash flow from operating activities	51			46	10,9%
Ordinary annual dividend per share, kronor	2,75	2,65	3,8%	2,50	10,0%

Consensus data from Factset